Overall Score

Financial Health

Liquidity remains solid with a current ratio of 2.43 and quick ratio of 1.93.

Leverage is modest, with debt-to-equity at 0.19 and debt-to-assets at 0.13.

Cash generation is weak, as operating cash flow margin is only 1.5% and free cash flow remains negative.

Interest coverage is strong at 22.3x, reducing near-term refinancing risk.

Profitability

Margins remain under pressure, with gross margin at 16.1% and operating margin at -19.5%.

Returns are still negative across the board, including ROE of -12.7% and ROIC of -7.9%.

Asset efficiency is mediocre, with asset turnover at 0.55x and fixed asset turnover at 1.90x.

Valuation

Valuation remains inexpensive on sales and book value, with P/S at 0.64x and P/B at 0.50x.

The market is pricing in distress, as earnings and free cash flow are negative and EV/EBITDA is not meaningful.

Net cash and low leverage support the balance-sheet discount.

Growth

Revenue per share is $4.88, but profitability remains negative, limiting quality of growth.

Working capital is positive at $96.8M, but operating cash flow conversion is still weak.

No recent news indicates a clear catalyst for faster growth.